Biotechnology company Circio Holding ASA (OSE:CRNA) and Entos Pharmaceuticals U.K. Ltd, a clinical-stage genetic medicines company, on Thursday announced a research collaboration to advance circular RNA delivery technology.

This partnership will combine Circio's circVec DNA vectors with Entos' Fusogenix PLV nucleic acid delivery platform.

The collaboration aims to improve delivery efficiency and reduce toxicity compared to lipid nanoparticle formulations. Entos will develop and validate PLV formulations of circVec DNA vectors and conduct in vivo testing.

Initial data is expected within three to six months. If successful, the results could support further development of novel, repeat-dosable therapeutic candidates for genetic medicine, chronic disease and vaccines.

Financial terms of the agreement were not disclosed.